To: Director of IHS Maternal & Child Health Program  
IHS Area Chief Medical Officers  
IHS Area Immunization Coordinators  
Tribal Epidemiology Centers

From: Uzo Chukwuma, IHS Immunization Program Manager

Subject: Fourth Quarter FY 2021 Immunization Report (July 1, 2021 – September 30, 2021)

Date: November 9, 2021

The Indian Health Service, Tribal and Urban Indian immunization programs report on the immunization status of American Indian and Alaska Native (AI/AN) children 3-27 months of age, 19 – 35 months of age, Adolescents 13 – 17 years of age and Adults. They also report on influenza vaccine coverage for all age groups. These reports are submitted to the IHS Division of Epidemiology and Disease Prevention on a quarterly basis.

3-27 Month Old Report

The 3–27 month report is designed to help programs ensure timely vaccination and identify children who may be falling behind so they can be brought up to date. The criteria listed below are used to monitor coverage in the following age groups:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Vaccines</th>
<th>Age Group</th>
<th>Vaccines</th>
</tr>
</thead>
</table>
| 3-4 months | • DTAP1  
  • IPV 1  
  • Hib 1  
  • Hepatitis B 1  
  • PCV1  
  • *(ROTA1)*† | 16-18 months | • DTAP 3  
  • IPV 2  
  • MMR 1  
  • Hib 2/3  
  • Hepatitis B 2  
  • Varicella  
  • PCV3  
  • *(ROTA3)*† |
| 5-6 Months | • DTAP 2  
  • IPV 2  
  • Hib 2  
  • Hepatitis B 2  
  • PCV2  
  • *(ROTA2)*† | 19-23 months | • DTAP 4  
  • IPV 3  
  • MMR 1  
  • Hib 3/4  
  • Hepatitis B 3  
  • Varicella  
  • PCV4  
  • *(ROTA3)*† |
| 7-15 months | • DTAP 3  
  • IPV 2  
  • Hib 2  
  • Hepatitis B 2  
  • PCV3  
  • *(ROTA3)*† | 24-27 months | • DTAP 4  
  • IPV 3  
  • MMR 1  
  • Hib 3/4  
  • Hepatitis B 3  
  • Varicella  
  • PCV4  
  • *(ROTA3)*†  
  • *(Hepatitis A1)*† |

Rotavirus vaccine (ROTA) and hepatitis A, though recommended, are not included in overall age appropriate coverage calculations. Data on ROTA and hepatitis A vaccine coverage are reported where available.
For FY21 Q4, 12 IHS Areas submitted immunization reports from IHS, Tribal, and Urban Indian health centers (I/T/U). This composite report provides information on the immunization status of 19,097 children 3-27 months old. Of these, 10,705/19,097 or 56.1% received all age-appropriate vaccinations compared to 58.1% (11,268/19,408) of children 3-27 months in the 3rd Quarter of FY21 [Figure 1].

Figure 1

Age Appropriate Immunization Coverage
3-27 Month Olds
FY04 Q1 - FY21 Q4, IHS National

VAR and PCV4 added to age appropriate coverage

Age Appropriate Coverage
The Two year old report (children 19-35 months old) is used to monitor progress towards the GPRA childhood immunization indicator.

Starting in 2011, the vaccines series measure used to monitor coverage in this age group is, the 4:3:1:3*:3:1:4 (4 DTaP, 3 IPV, 1 MMR, the full series of Hib (3 or 4 doses, depending on product type of vaccine), 3 Hep B, 1 VAR, 4 PCV) series. The HP 2020 goal is 80% with the 4:3:1:3*:3:1:4 series, and 90% coverage with each individual vaccine in the series.

**4:3:1:3*:3:1:4 Series**
In FY21 Q3, 12 IHS Areas completed reports. Overall 57.5% (10,007/17,394) of two year olds had completed the 4:3:1:3*:3:1:4 vaccine series compared to 57.8% (9,003/15,579) in FY21 Q3.

**Figure 2**

**4:3:1:3*:3:1:4 Coverage**
2 Year Old
FY09 Q1 – FY21 Q4, IHS National

4:3:1:3*:3:1:4 series includes 4 doses of DTaP, 3 doses of Polio (IPV), 1 dose of MMR, the full series of Hib (3 or 4 doses, depending on product type of vaccine), 3 doses of Hep B, 1 dose of Varicella and 4 doses of PCV.
This report collects data on adolescents 13 – 17 years who meet the “Active Clinical User“ definition (e.g. 2 visits in the last 3 years) and is designed to monitor uptake of recommended adolescent vaccines (e.g. tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap], meningococcal conjugate [MCV4], and human papillomavirus [HPV] vaccines) and monitor coverage in the adolescent population with the following recommended childhood vaccines: 1 dose of Td or Tdap, 3 doses of hepatitis B, 2 doses of MMR, and 2 doses of Varicella/Hx of chickenpox. A summary of immunization coverage for 13 year olds and 13 –17 year olds with these vaccines is included below.

**Immunization Coverage for 13 year olds**

For FY21 Q4, the 12 IHS Areas combined reported on 12,653 thirteen year olds compared to 12,715 thirteen year olds in the FY21 Q3 report.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>IHS All Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose of Tdap</td>
<td>87.6% (11,081/12,653)</td>
<td>78% - 98%</td>
</tr>
<tr>
<td>1 dose of MENCACWY</td>
<td>85% (10,758/12,653)</td>
<td>71% - 98%</td>
</tr>
<tr>
<td>1 dose of HPV</td>
<td>80% (10,111/12,640)</td>
<td>58% - 94%</td>
</tr>
</tbody>
</table>

For FY21 Q4, 87.6% received 1 dose of Tdap vaccine, 85% had received 1 dose of MENCACWY vaccine, and 80% received 1 dose of HPV [Figure 3] compared to 87.8% received 1 dose of Tdap vaccine, 85% had received 1 dose of MENCACWY vaccine, and 79.4% received 1 dose of HPV for FY21 Q3..

**Figure 3**

*Adolescent Vaccines Coverage 13 Year Old FY10 Q4 – FY21 Q4, IHS National*
Immunization Coverage for 13 – 17 year olds

For FY21 Q4, the 12 IHS Areas combined reported on 59,458 13–17 year olds compared to the FY21 Q3 report which included 61,769 13–17 year olds.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>IHS All Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 doses of Hepatitis B</td>
<td>95.9% (56,991/59,458)</td>
<td>79% - 99%</td>
</tr>
<tr>
<td>2 doses of MMR vaccine</td>
<td>94.8% (56,390/59,458)</td>
<td>78% - 99%</td>
</tr>
<tr>
<td>2 doses of Varicella vaccine or had a documented history of chickenpox</td>
<td>94.6% (56,250/59,458)</td>
<td>75% - 99%</td>
</tr>
<tr>
<td>1 dose of Tdap vaccine</td>
<td>91.2% (54,207/59,458)</td>
<td>75% - 99%</td>
</tr>
<tr>
<td>1 dose of MENACWY vaccine</td>
<td>89.4% (53,140/59,458)</td>
<td>65% - 99%</td>
</tr>
<tr>
<td>1 dose of HPV vaccine</td>
<td>84.3% (50,057/59,353)</td>
<td>60% - 99%</td>
</tr>
</tbody>
</table>

For FY21 Q4, 91.2% received 1 dose of Tdap vaccine, 89.4% had received 1 dose of MENACWY vaccine, and 84.3% received 1 dose of HPV vaccine [Figure 4] compared to 91.4% received 1 dose of Tdap vaccine, 89.4% had received 1 dose of MENACWY vaccine, and 84.3% received 1 dose of HPV vaccine for FY21 Q3.

Figure 4

[Bar chart showing adolescent vaccines coverage for FY20 Q4 - FY21 Q4, IHS National]
HPV Coverage for 13 – 17 year olds

For **FY21 Q4** the 12 IHS Areas combined reported on 30,066 females in the group and 29,287 males in the group for a total of 59,353 13–17 years of age compared to FY21 Q3, which included 61,651 13-17 year olds. For FY21 Q4, 84.3% (50,057/59,458) had received 1 dose of HPV, 69.6% (41,300/59,458) had received 2 doses of HPV and 13.1% (7,750/59,458) had received 3 doses of HPV [Figure 5].

For **FY21 Q4**, coverage by Area ranged from 64% - 97% for HPV1, 50% - 91% for HPV2, and 28% – 63% for HPV3.

* NOTE: *IHS implemented the 2-dose HPV schedule into the clinical decision support, however it is not reflected in the reports. Therefore, the HPV 2nd and 3rd dose coverage currently do not reflect the true coverage.*

**Figure 5**
The Adult Immunization Report was collected for the first time in FY12 Q4. This report collects data on patients meeting the “Active Clinical User” definition (e.g. 2 visits in the last 3 years) and reports vaccination rates for the following vaccines and age groups: Tdap in those 19 years+; HPV 1, 2 and 3 doses in Females 19-26 years; HPV 1, 2, and 3 doses in Males 19-21 years; Zoster vaccine in those 60 years+, and Pneumococcal polysaccharide vaccine at or after age 65 years.

For FY21 Q4 data was collected from all of the 12 IHS Areas on 439,913 active clinical patients 19 years and older compared to FY21 Q3 which included 417,167. Below is a chart with the coverage for each of the adult vaccines.

<table>
<thead>
<tr>
<th>Vaccine Description</th>
<th>All IHS Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose of Tdap (19 years and older)</td>
<td>64.5% (283,794/439,913)</td>
<td>54% - 86%</td>
</tr>
<tr>
<td>1 dose of HPV females (19-26 years)</td>
<td>69.7% (27,362/39,253)</td>
<td>46% - 87%</td>
</tr>
<tr>
<td>3 doses of HPV females (19-26 years)</td>
<td>51% (20,022/39,253)</td>
<td>32% - 80%</td>
</tr>
<tr>
<td>1 dose of HPV males (19-21 years)</td>
<td>65.7% (7,573/11,524)</td>
<td>38% - 88%</td>
</tr>
<tr>
<td>3 dose of HPV males (19-21 years)</td>
<td>37.2% (4,288/11,524)</td>
<td>21% - 62%</td>
</tr>
<tr>
<td>1 dose of Zoster (60 years and older)</td>
<td>45.8% (53,217/116,204)</td>
<td>32% - 78%</td>
</tr>
<tr>
<td>1 dose of Pneumo at/after 65 years</td>
<td>71.4% (57,061/79,875)</td>
<td>51% - 86%</td>
</tr>
</tbody>
</table>

**Figure 6**

Adult Vaccines Coverage
FY20 Q4 - FY21 Q4, IHS National
Adult Composite Report

The Adult composite measure data is included in the Adult Immunization Report and is being collected for the first time in FY17 Q3. This report collects data on patients meeting the “Active Clinical User” definition (e.g. 2 visits in the last 3 years) and reports vaccination rates for the following vaccines and age groups: 19-59 years with Tdap ever and Tdap/Td <10 years; 60-64 years with Tdap ever and Tdap/Td <10 years and Zoster; 65+ years with Tdap ever and Tdap/Td <10 years and Zoster and Pneumo; and 19 years and older with appropriately vaccinated per age recommendation.

<table>
<thead>
<tr>
<th></th>
<th>All IHS Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tdap ever and Tdap/Td &lt; 10 years (19-59 years)</td>
<td>71.2% (228,196/320,595)</td>
<td>53% - 95%</td>
</tr>
<tr>
<td>Tdap ever and Tdap/Td &lt; 10 years (60-64 years)</td>
<td>11.1% (4,382/39,572)</td>
<td>14% - 88%</td>
</tr>
<tr>
<td>Tdap ever and Tdap/Td &lt; 10 years and Zoster and Pneumo (65 years and older)</td>
<td>47.4% (37,754/79,597)</td>
<td>27% - 91%</td>
</tr>
<tr>
<td>Appropriately vaccinated per age recommendation (19 years and older)</td>
<td>60% (264,127/439,913)</td>
<td>47% - 86%</td>
</tr>
</tbody>
</table>

Figure 7

Adult Vaccine Composite Measures*
Appro priately Vaccinated Per Age Recommendations
FY20 Q4 - FY21 Q4, IHS National

* 19-59 years with Tdap ever and Tdap/Td <10 years; 60-64 years with Tdap ever and Tdap/Td <10 years and Zoster; 65+ years with Tdap ever and Tdap/Td <10 years and Zoster and Pneumo; and 19 years and older with appropriately vaccinated per age recommendation.